• Je něco špatně v tomto záznamu ?

Aspirin and Hemocompatibility After LVAD Implantation in Patients With Atherosclerotic Vascular Disease: A Secondary Analysis From the ARIES-HM3 Randomized Clinical Trial

F. Gustafsson, N. Uriel, I. Netuka, JN. Katz, FD. Pagani, JM. Connors, UP. Jorde, D. Zimpfer, Y. Pya, J. Conway, A. Anyanwu, AM. Scandroglio, N. Sulemanjee, P. Atluri, M. Keebler, CH. Selzman, JD. Alexis, C. Hayward, J. Henderson, N. Dirckx, C....

. 2025 ; 10 (3) : 235-242. [pub] 20250301

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie, multicentrická studie, komentáře

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009701

IMPORTANCE: The Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure (ARIES-HM3) study demonstrated that aspirin may be safely eliminated from the antithrombotic regimen after HeartMate 3 (HM3 [Abbott Cardiovascular]) left ventricular assist device (LVAD) implantation. This prespecified analysis explored whether conditions requiring aspirin (prior percutaneous coronary intervention [PCI], coronary artery bypass grafting [CABG], stroke, or peripheral vascular disease [PVD]) would influence outcomes differentially with aspirin avoidance. OBJECTIVE: To analyze aspirin avoidance on hemocompatibility-related adverse events (HRAEs) at 1 year after implant in patients with a history of CABG, PCI, stroke, or PVD. DESIGN, SETTING, AND PARTICIPANTS: This was an international, multicenter, prospective, double-blind, placebo-controlled, randomized clinical trial including patients implanted with a de novo HM3 LVAD across 51 centers. Data analysis was conducted from April to July 2024. INTERVENTIONS: Patients were randomized in a 1:1 ratio to receive aspirin (100 mg per day) or placebo, in addition to a vitamin K antagonist (VKA) targeted to an international normalized ratio of 2 to 3 in both groups. MAIN OUTCOMES AND MEASURES: Primary end point (assessed for noninferiority) was a composite of survival free of any nonsurgical (>14 days after implant) HRAEs including stroke, pump thrombosis, bleeding, and arterial peripheral thromboembolism at 12 months. Secondary end points included nonsurgical bleeding, stroke, and pump thrombosis events. RESULTS: Among 589 of 628 patients (mean [SD] age, 57.1 [13.7] years; 456 male [77.4%]) who contributed to the primary end point analysis, a history of PCI, CABG, stroke, or PVD was present in 41% (240 of 589 patients). There was no interaction between the presence of an atherosclerotic vascular condition and effect of aspirin compared with placebo (P for interaction= .23). The preset 10% noninferiority margin was not crossed for the studied subgroup of patients. Thrombotic events were rare, with no differences between aspirin and placebo in patients with and without vascular disease (P for interaction = .77). Aspirin treatment was associated with a higher rate of nonsurgical major bleeding events in the group with prior vascular condition history compared with those without aspirin (rate ratio for placebo compared with aspirin, 0.52; 95% CI, 0.35-0.79). CONCLUSIONS AND RELEVANCE: Results of this prespecified analysis of the ARIES-HM3 randomized clinical trial demonstrate that in patients with advanced heart failure who have classical indications for antiplatelet therapy use at the time of LVAD implantation, aspirin avoidance was safe and not associated with increased thrombosis risk. Importantly, elimination of aspirin was associated with no increased thrombosis but a reduction in nonsurgical bleeding events in patients with a history of PCI, CABG, stroke, or PVD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04069156.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009701
003      
CZ-PrNML
005      
20250429135431.0
007      
ta
008      
250415s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1001/jamacardio.2024.4849 $2 doi
035    __
$a (PubMed)39774588
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Gustafsson, Finn $u Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
245    10
$a Aspirin and Hemocompatibility After LVAD Implantation in Patients With Atherosclerotic Vascular Disease: A Secondary Analysis From the ARIES-HM3 Randomized Clinical Trial / $c F. Gustafsson, N. Uriel, I. Netuka, JN. Katz, FD. Pagani, JM. Connors, UP. Jorde, D. Zimpfer, Y. Pya, J. Conway, A. Anyanwu, AM. Scandroglio, N. Sulemanjee, P. Atluri, M. Keebler, CH. Selzman, JD. Alexis, C. Hayward, J. Henderson, N. Dirckx, C. Gazzola, MR. Mehra, ARIES Investigators
520    9_
$a IMPORTANCE: The Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure (ARIES-HM3) study demonstrated that aspirin may be safely eliminated from the antithrombotic regimen after HeartMate 3 (HM3 [Abbott Cardiovascular]) left ventricular assist device (LVAD) implantation. This prespecified analysis explored whether conditions requiring aspirin (prior percutaneous coronary intervention [PCI], coronary artery bypass grafting [CABG], stroke, or peripheral vascular disease [PVD]) would influence outcomes differentially with aspirin avoidance. OBJECTIVE: To analyze aspirin avoidance on hemocompatibility-related adverse events (HRAEs) at 1 year after implant in patients with a history of CABG, PCI, stroke, or PVD. DESIGN, SETTING, AND PARTICIPANTS: This was an international, multicenter, prospective, double-blind, placebo-controlled, randomized clinical trial including patients implanted with a de novo HM3 LVAD across 51 centers. Data analysis was conducted from April to July 2024. INTERVENTIONS: Patients were randomized in a 1:1 ratio to receive aspirin (100 mg per day) or placebo, in addition to a vitamin K antagonist (VKA) targeted to an international normalized ratio of 2 to 3 in both groups. MAIN OUTCOMES AND MEASURES: Primary end point (assessed for noninferiority) was a composite of survival free of any nonsurgical (>14 days after implant) HRAEs including stroke, pump thrombosis, bleeding, and arterial peripheral thromboembolism at 12 months. Secondary end points included nonsurgical bleeding, stroke, and pump thrombosis events. RESULTS: Among 589 of 628 patients (mean [SD] age, 57.1 [13.7] years; 456 male [77.4%]) who contributed to the primary end point analysis, a history of PCI, CABG, stroke, or PVD was present in 41% (240 of 589 patients). There was no interaction between the presence of an atherosclerotic vascular condition and effect of aspirin compared with placebo (P for interaction= .23). The preset 10% noninferiority margin was not crossed for the studied subgroup of patients. Thrombotic events were rare, with no differences between aspirin and placebo in patients with and without vascular disease (P for interaction = .77). Aspirin treatment was associated with a higher rate of nonsurgical major bleeding events in the group with prior vascular condition history compared with those without aspirin (rate ratio for placebo compared with aspirin, 0.52; 95% CI, 0.35-0.79). CONCLUSIONS AND RELEVANCE: Results of this prespecified analysis of the ARIES-HM3 randomized clinical trial demonstrate that in patients with advanced heart failure who have classical indications for antiplatelet therapy use at the time of LVAD implantation, aspirin avoidance was safe and not associated with increased thrombosis risk. Importantly, elimination of aspirin was associated with no increased thrombosis but a reduction in nonsurgical bleeding events in patients with a history of PCI, CABG, stroke, or PVD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04069156.
650    _2
$a lidé $7 D006801
650    12
$a Aspirin $x terapeutické užití $7 D001241
650    12
$a podpůrné srdeční systémy $7 D006353
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a senioři $7 D000368
650    _2
$a prospektivní studie $7 D011446
650    _2
$a inhibitory agregace trombocytů $x terapeutické užití $7 D010975
650    _2
$a srdeční selhání $7 D006333
650    _2
$a ateroskleróza $7 D050197
650    _2
$a cévní mozková příhoda $x prevence a kontrola $7 D020521
650    _2
$a koronární angioplastika $x metody $7 D062645
650    _2
$a fibrinolytika $x terapeutické užití $7 D005343
650    _2
$a krvácení $x chemicky indukované $7 D006470
650    _2
$a trombóza $x prevence a kontrola $7 D013927
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
655    _2
$a komentáře $7 D016420
700    1_
$a Uriel, Nir $u Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York
700    1_
$a Netuka, Ivan $u Insitute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Katz, Jason N $u NYU Grossman School of Medicine and Bellevue Hospital, New York, New York
700    1_
$a Pagani, Francis D $u University of Michigan, Ann Arbor
700    1_
$a Connors, Jean M $u Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
700    1_
$a Jorde, Ulrich P $u Montefiore Einstein Center for Heart and Vascular Care, New York, New York
700    1_
$a Zimpfer, Daniel $u Medical University of Vienna, Vienna, Austria
700    1_
$a Pya, Yuriy $u University Medical Center, Astana, Kazakhstan
700    1_
$a Conway, Jennifer $u University of Alberta Hospital, Edmonton, Alberta, Canada
700    1_
$a Anyanwu, Anelechi $u Mount Sinai Medical Center, New York, New York
700    1_
$a Scandroglio, Anna Mara $u Ospedale San Raffaele, Milan, Italy
700    1_
$a Sulemanjee, Nasir $u Aurora St Luke's Medical Center, Milwaukee, Wisconsin
700    1_
$a Atluri, Pavan $u Hospital of the University of Pennsylvania, Philadelphia
700    1_
$a Keebler, Mary $u University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
700    1_
$a Selzman, Craig H $u University of Utah Hospital, Salt Lake City
700    1_
$a Alexis, Jeffrey D $u University of Rochester Medical Center, Rochester, New York
700    1_
$a Hayward, Christopher $u St Vincent's Hospital, Sydney, New South Wales, Australia
700    1_
$a Henderson, John $u Abbott, Chicago, Illinois
700    1_
$a Dirckx, Nicholas $u Abbott, Chicago, Illinois
700    1_
$a Gazzola, Carlo $u Abbott, Chicago, Illinois
700    1_
$a Mehra, Mandeep R $u Brigham and Women's Hospital Heart and Vascular Center, Center for Advanced Heart Disease, Harvard Medical School, Boston, Massachusetts
710    2_
$a ARIES Investigators
773    0_
$w MED00191356 $t JAMA cardiology $x 2380-6591 $g Roč. 10, č. 3 (2025), s. 235-242
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39774588 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135427 $b ABA008
999    __
$a ok $b bmc $g 2311213 $s 1246782
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 10 $c 3 $d 235-242 $e 20250301 $i 2380-6591 $m JAMA cardiology $n JAMA Cardiol $x MED00191356
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace